Stock PCSA PROCESSA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Processa Pharmaceuticals, Inc.

Equities

PCSA

US74275C3043

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-08 EDT 		5-day change 1st Jan Change
2.48 USD 0.00% Intraday chart for Processa Pharmaceuticals, Inc. +11.71% -62.94%
04-30 Processa Pharmaceuticals, Inc. Names Steven Cha as Senior Vice President of Clinical Research CI
04-30 Certain Common Warrants of Processa Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-APR-2024. CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Top Premarket Decliners
MT
Processa Pharmaceuticals, Inc. Presents Two Abstracts At the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1B Trial
CI
Processa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Processa Pharmaceuticals Shares More Than Double After Completing Safety Evaluation of Cancer Treatment
DJ
Processa Pharmaceuticals, Inc. Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses
CI
Processa Plans to Expand NGC-Cap Program Into Breast Cancer; Shares Soar
MT
Processa Pharma Shares Jump Premarket After Expansion of NGC-Cap Program
DJ
Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer
CI
Processa Pharmaceuticals, Inc. Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety over Capecitabine
CI
Processa Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Processa Pharmaceuticals, Inc. Provides Data Update Supporting A Potential Personalized Treatment Approach for Improved Cancer Care
CI
Processa Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Processa Pharmaceuticals, Inc. Announces to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative
CI
Processa Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Processa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Processa Pharmaceuticals, Inc. Announces Prioritization on Development of Next Generation Chemotherapies
CI
Processa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A Trial
CI
Processa Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Processa Pharmaceuticals, Inc. Announces Positive Gastric Emptying Results from its Pcs12852 Phase 2A Trial in Patients
CI
Processa Successfully Identifies Next Generation Capecitabine Dosage Regimens for Phase 2B Trial
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PCSA Stock
  4. News Processa Pharmaceuticals, Inc.
  5. Highlights
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW